An Antimicrobial Treatment Assessment of Serratia marcescens Bacteremia and Endocarditis

Douglas Slain; Catessa Howard; C Garret Cooper

doi:10.3389/frabi.2022.942721

An Antimicrobial Treatment Assessment of Serratia marcescens Bacteremia and Endocarditis

Front Antibiot. 2022 Jun 29:1:942721. doi: 10.3389/frabi.2022.942721. eCollection 2022.

Authors

Douglas Slain¹, Catessa Howard², C Garret Cooper³

Affiliations

¹ Department of Clinical Pharmacy, School of Pharmacy, Section of Infectious Diseases, School of Medicine, West Virginia University, Morgantown, WV, United States.
² Department of Pharmacy, West Virginia University (WVU) Medicine, Morgantown, WV, United States.
³ Department of Medicine, West Virginia University School of Medicine, Morgantown, WV, United States.

Abstract

We assessed the treatment of Serratia marcescens bacteremia and endocarditis in one of the largest single center studies. We could not identify an advantage with any particular antibiotic treatment regimen in this study. Induction of AmpC or selection of ESBL organisms was not displayed by any of the organisms.

Keywords: AmpC β-lactamase; Serratia marcescens; antibacterials; bacteremia; endocarditis.